Kaposi Sarcoma Updates

Etemad, Shervin; Dewan, Anna K.

doi:10.1016/j.det.2019.05.008

Cited by 58 publications

(60 citation statements)

References 75 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The reported upregulation of PD‐1/PD‐L1 expression supports that KS can be treated with anti‐PD‐1/PD‐L1 immunotherapy. Similar to the favorable treatment response of patients with polyomavirus‐related Merkel cell carcinoma, cases with endemic KS and HIV‐associated refractory KS show a promising response to the anti‐PD‐1 antibody nivolumab 20,30,31 . This response has even been observed in PD‐1/PD‐L1‐negative cases 17 .…”

Section: Discussionmentioning

confidence: 77%

“…Similar to the favorable treatment response of patients with polyomavirus-related Merkel cell carcinoma, cases with endemic KS and HIV-associated refractory KS show a promising response to the anti-PD-1 antibody nivolumab. 20,30,31 This response has even been observed in PD-1/PD-L1-negative cases. 17 Most recently, a phase II single-arm prospective study was performed of nivolumab and ipilimumab.…”

Section: Discussionmentioning

confidence: 87%

See 1 more Smart Citation

PD‐1 and PD‐L1 expression in Kaposi sarcoma: A comparative study according to the pathological stage and clinical characteristics

et al. 2020

View full text Add to dashboard Cite

Background Kaposi sarcoma (KS) is a mesenchymal tumor with distinct histopathological features according to stage of progression. Programmed death‐1 (PD‐1) and its ligand PD‐L1 play major roles in the immune escape strategy of tumors. Objectives This study evaluated expression of PD‐1 and PD‐L1 in various stages of KS and investigated associations between their expression and clinical characteristics. Methods Fifty cases with histopathologically diagnosed KS were classified as early or late stage. These specimens were stained with anti‐PD‐1 and anti‐PD‐L1 antibodies. The extent of expression in the intratumoral and peritumoral areas was judged by two dermatopathologists. Results PD‐1 and PD‐L1 were expressed in 72.2% (13/18) and 11.1% (2/18) of early‐stage cases, respectively, compared with 43.8% (14/32) and 28.1% (9/32) of late‐stage cases, respectively. At the late stage, PD‐1 expression was significantly higher in the peritumoral area than in the intratumoral area (P = 0.001). PD‐1 expression in the intratumoral area was significantly higher at the early stage than at the late stage (P = 0.013). PD‐L1 expression in the peritumoral area was significantly higher at the late stage than at the early stage (P = 0.038). Conclusions The pattern of PD‐1 and PD‐L1 expression differs according to the stage of KS, but is unaffected by clinical variables.

show abstract

Section: Discussionmentioning

confidence: 77%

Section: Discussionmentioning

confidence: 87%

PD‐1 and PD‐L1 expression in Kaposi sarcoma: A comparative study according to the pathological stage and clinical characteristics

et al. 2020

View full text Add to dashboard Cite

show abstract

“…It is important to recognize that erythema in darker-pigmented individuals can appear violaceous and that epidermal death can appear dusky or gray. 6,7 Another layer of difficulty was management of PF during the COVID-19 pandemic. Though rituximab was offered, the patient had concerns beginning immunosuppression due to the unclear safety of rituximab affecting susceptibility to the viral infection.…”

Section: Abbreviations Usedmentioning

confidence: 99%

Pemphigus foliaceus presenting with violaceous, painful nodules and an aberrant auto-antibody expression in a Latino patient

Patel

González

et al. 2021

JAAD Case Reports

View full text Add to dashboard Cite

“…It normally involves the skin, oral cavity and gastrointestinal tract but can also involve distant tissues such as lungs, lymphatic system and liver. 7 The lesions are usually pink, red or purple that do not pale to pressure and asymptomatic, however, they can become exophytic and ulcerated associated with painful edema. 8 Although the lesions are usually characteristic, the diagnosis must be confirmed histologically.…”

Section: Introductionmentioning

confidence: 99%

Kaposi's sarcoma a series of cases and review of the literature

Báez¹

2021

MOJCR

View full text Add to dashboard Cite

Introduction: Kaposi's sarcoma is a neoplasm associated with the Human Immunodeficiency Virus (HIV) - AIDS especially in advanced stages, in Quintana Roo HIV-AIDS ranks first in the country. Methodology: A series of 22 cases with diagnosis confirmed by biopsy attended by the oncology service of HGR No. 17 is presented. Results: They were classified as low risk (4); three of them with complete response. High risk (18); fifteen accepted chemotherapy. Nine (60%) received liposomal doxorubicin and six (40%) paclitaxel; of these, four had a complete response, one partial response, six with stable disease and five with disease progression that required a second line. The presence of adverse effects associated with chemotherapy treatment was documented in six patients classified as high risk (40%). Conclusions: Clinical interventions with therapeutic trials are necessary, since the available evidence dates from periods of more than 10 years ago. HIV patients require continuous monitoring and clinical trials to improve the therapeutic options available to treat one of the most common oncological diseases in this population such as Kaposi's Sarcoma.

show abstract

Kaposi Sarcoma Updates

Cited by 58 publications

References 75 publications

PD‐1 and PD‐L1 expression in Kaposi sarcoma: A comparative study according to the pathological stage and clinical characteristics

PD‐1 and PD‐L1 expression in Kaposi sarcoma: A comparative study according to the pathological stage and clinical characteristics

Pemphigus foliaceus presenting with violaceous, painful nodules and an aberrant auto-antibody expression in a Latino patient

Kaposi's sarcoma a series of cases and review of the literature

Contact Info

Product

Resources

About